Myiris.com - 1 hour ago
The scrip has touched an intra - day high of Rs 214.25 and low of Rs 197.05.The total volume of shares traded at the BSE is 86,499.In the earlier session , the shares rose 7.73 % , or Rs 14.25 ...
Fresh News - 36 minutes ago
By Indo - Asian News Service on Thursday , November 6 , 2008Cipla Medpro Manufacturing ( CMM ) , a wholly - owned subsidiary of South African generic drug manufacturer Cipla Medpro , will stop ...
Business Report - 1 hour ago
Durban - Cipla Medpro Manufacturing , a wholly owned subsidiary of Cipla Medpro , would produce antiretrovirals ( ARVs ) in - house from next year instead of buying them from India , Mark Gardiner ...
Business Report - 37 minutes ago
Durban - Cipla Medpro Manufacturing , a wholly owned subsidiary of Cipla Medpro , would produce antiretrovirals ( ARVs ) in - house from next year instead of buying them from India , Mark Gardiner ...
Business Report - 50 minutes ago
Cipla Medpro Manufacturing , a wholly owned subsidiary of Cipla Medpro , would produce antiretrovirals ( ARVs ) in - house from next year instead of buying them from India , Mark Gardiner , the ...
Business Standard - 29 minutes ago
The September 2008 quarter was the fifth consecutive quarter of good revenue growth for pharma major Cipla , helped to an extent by the depreciating rupee.The company registered a 23 per cent ...
Times of India - 38 minutes ago
NEW DELHI : Amidst all the gloom confronting the economy , the pharma sector posted a robust growth of over 14 % in September , with Cipla emerging as leader in the domestic retail market with ...
Livemint - 1 hour ago
Cipla has reported strong growth in revenues to beat our expectation.Revenue for the quarter grew 23.3 % to Rs13 . 55 billion as compared to Rs10 . 98 billion in Q2FY08.Domestic formulation sales ...
Economic Times - 28 minutes ago
22 Oct , 2008 , 2058 hrs IST , PTINEW DELHI : Drug maker Cipla Ltd on Wednesday reported a decline of 20.55 per cent in its net profit at Rs 151.43 crore for the quarter ended September 30 , ...
